The Impact of Free Fatty Acid (FFA-) Suppression on Myocardial Lipids and Function in Patients With Type 2 Diabetes (HYPOTESIS)
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
There is evidence that inhibition of FFA-release by acipimox is associated with a significant decrease in myocardial lipid content (MYCL) as well as the ejection fraction (as a marker of systolic left ventricular function) in healthy subjects, indicating, that the heart is dependent on a constant supply of free fatty acids in order to guarantee normal cardiac function, and it further indicates, that the heart is not able to cover its energy demand by switching to glucose oxidation.
Since that phenomenon, better known as "metabolic inflexibility" has been mainly described in patients with diabetes, we aim to investigate the impact of FFA-inhibition on MYCL and cardiac function in patients with overt type 2 diabetes.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Type 2 Diabetes
- HbA1C >6%
Exclusion criteria
- Insulin therapy (except: BOT=basal supported oral therapy)
- Known heart disease including coronary artery disease, cardiomyopathy, history of cardiac surgery
- Known intolerance against niacins
- Known contra-indications against magnetic resonance (MR-) examinations
Trial design
Primary purpose
Allocation
Interventional model
Masking
8 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal